|
J Biol Chem, Vol. 275, Issue 8, 5337-5346, February 25, 2000
Kv4.2 Phosphorylation by Cyclic AMP-dependent Protein
Kinase*
Anne E.
Anderson §,
J. Paige
Adams¶,
Yan
Qian¶,
Richard G.
Cook ,
Paul J.
Pfaffinger¶, and
J. David
Sweatt¶
From the Departments of Pediatrics and Neurology,
¶ Division of Neuroscience, Department of Microbiology and
Immunology, Baylor College of Medicine, Houston, Texas 77030
 |
ABSTRACT |
Recent evidence suggests that
K+ channels composed of Kv4.2 -subunits underlie a
transient current in hippocampal CA1 neurons and ventricular myocytes,
and activation of the cAMP second messenger cascade has been shown to
modulate this transient current. We determined if Kv4.2 -subunits
were directly phosphorylated by cAMP-dependent protein
kinase (PKA). The intracellular domains of the amino and carboxyl
termini of Kv4.2 were expressed as glutathione S-transferase fusion protein constructs; we observed that
both of these fusion proteins were substrates for PKA in
vitro. By using phosphopeptide mapping and amino acid sequencing,
we identified PKA phosphorylation sites on the amino- and
carboxyl-terminal fusion proteins corresponding to Thr38
and Ser552, respectively, within the Kv4.2 sequence.
Kinetic characterization of the PKA sites demonstrated phosphorylation
kinetics comparable to Kemptide. To evaluate PKA site phosphorylation
in situ, phospho-selective antisera for each of the sites
were generated. By using COS-7 cells expressing an EGFP-Kv4.2 fusion
protein, we observed that stimulation of the endogenous PKA cascade
resulted in an increase in phosphorylation of Thr38 and
Ser552 within Kv4.2 in the intact cell. We also observed
modulation of PKA phosphorylation at these sites within Kv4.2 in
hippocampal area CA1. These results provide insight into likely sites
of regulation of Kv4.2 by PKA.
 |
INTRODUCTION |
Voltage-dependent K+ channels play a
significant role in regulating membrane excitability (1). In both
hippocampal pyramidal neurons and ventricular myocytes, a
voltage-dependent, A-type K+ channel expressing
a transient current is present in high density (2-4). Hoffman et
al. (5) recently reported dense localization of
voltage-dependent, A-type K+ channels to the
distal dendrites of hippocampal CA1 pyramidal neurons. The A-type
K+ current in the distal dendrites was found to limit
action potential initiation and back propagation into the dendrites and
thereby regulate the magnitude of the excitatory post-synaptic
potential in response to synaptic activity (5). Likewise in ventricular myocytes, the transient current plays a role in regulating action potential amplitude and in myocardial contractile force (6, 7). In
summary, there is strong evidence that transient K+
channels in both the hippocampus and myocardium significantly contribute to the regulation of membrane excitability in these regions.
The identity of the K+ channel subunit(s) responsible for
transient A-type currents in hippocampal pyramidal neurons and
ventricular myocytes is not conclusively known; however, several lines
of evidence support the hypothesis that this current is mediated, at
least in part, by channels containing Kv4.2, the Shal-type, K+ channel subunit proteins. 1) Kv4.2, forms
voltage-dependent, rapidly inactivating K+
channels and is selectively localized and abundantly expressed on the
soma and dendrites of dentate gyrus and CA1 and CA3 hippocampal neurons
(3, 8, 9). 2) Ultrastructural studies have demonstrated that Kv4.2 is
localized to the subsynaptic compartment (10). 3) In myocardium, Kv4.2
is more abundant in ventricular versus atrial myocytes and
is more abundant than other subfamily -subunits known to express a
transient current (3, 11). 4) In some mammalian species it has been
shown that the transient current occurs in a gradient across the
ventricular wall with expression being highest in the epicardial layers
(12, 13). As well, it has been shown in some species that the
expression of Kv4.2 also follows a gradient in the ventricular
myocardium (11). Therefore, both the localization and biophysical
properties of Kv4.2 are consistent with the idea that this channel
subunit contributes to A-type currents in ventricular myocytes and in
dendrites of hippocampal pyramidal neurons.
Protein phosphorylation plays a critical role in the regulation of ion
channel function and membrane excitability (14). It is known that some
of the voltage-dependent K+ channels are
regulated by protein phosphorylation. Voltage-dependent K+ channels are thought to be homo- or heterotetramers of
-subunits with each subunit characterized by six membrane-spanning
domains, a pore-forming region, and cytoplasmic amino- and
carboxyl-terminal domains (15-17). The -subunits are typically
associated with -, or ancillary, subunits; however, to date, the
ancillary subunits that are associated with Kv4.2 -subunits have not
been identified (2, 18). The majority of cases reported so far have
demonstrated kinase regulatory sites on the -subunits of
voltage-dependent K+ channels (19).
Furthermore, the recognized kinase regulatory sites lie in the
cytoplasmic domains of these channels.
PKA1 activation is a powerful
regulator of hippocampal neuron excitability (20). However, little is
known about the downstream molecular targets of PKA that directly
influence neuronal excitability. Hoffman and Johnston (21) have shown
that the voltage-dependent activation of dendritic A-type
channels is down-regulated by activation of PKA, strongly suggesting
that these channels are a molecular target for PKA. Based on both the
selective localization of Kv4.2 in hippocampal dendrites and the
demonstration by Hoffman and Johnston (21) that dendritic A-type
currents are regulated by PKA activation, one appealing hypothesis is
that PKA directly alters the properties of Kv4.2 by phosphorylation of
the channel -subunit.
Although there are no direct lines of evidence for PKA regulation of
transient currents in ventricular myocytes, it is known that
ventricular myocardial contractility is influenced by neurotransmitter systems such as the -adrenergic catecholaminergic system which result in downstream activation of the cAMP cascade (22, 23). Furthermore, it has been shown that in myocytes, transient channels thought to be composed of Kv4 subfamily -subunits are modulated by
additional second messenger systems (24). These findings further
support the idea that Kv4.2 may be a molecular target for second
messenger cascades involved in regulation of myocardial excitability.
The current study tests the hypothesis that the transient
K+ channel, Kv4.2, is a downstream target for the PKA
second messenger cascade. We determined that recombinant GST fusion
protein constructs of the amino and carboxyl termini of Kv4.2 are
substrates for PKA. The phosphorylation sites on the GST fusion
proteins were identified with phosphopeptide mapping and automated
amino acid sequencing of the recombinant proteins following
phosphorylation by PKA in vitro. Kinetic analysis revealed
that these sites are attractive PKA substrates with
Km and Vmax values that are
comparable to those of a well established PKA substrate, Kemptide. The
sequencing data for the PKA phosphorylation sites on Kv4.2 were then
used to generate phospho-site-selective antibodies, by using synthetic
phosphopeptides corresponding to the amino- and carboxyl-terminal
phosphorylation sites as antigens. These antibodies were then used to
quantitate changes in phosphorylation of Kv4.2 expressed in COS-7
cells. Activation of the PKA cascade in COS-7 cells expressing Kv4.2
results in an increase in immunoreactivity, indicating that the amino-
and carboxyl-terminal sites are phosphorylated within Kv4.2 in the
intact cell. In the final series of experiments the antibodies were
used to demonstrate modulation of PKA phosphorylation of Kv4.2 in
hippocampal area CA1.
 |
EXPERIMENTAL PROCEDURES |
Protein Expression and Purification--
The Kv4.2 amino- and
carboxyl-terminal domain proteins were expressed in Escherichia
coli as glutathione S-transferase (GST) fusion proteins
using methods modified from Hakes and Dixon (25). Plasmids containing
the amino-terminal (amino acid residues 1-133) and carboxyl-terminal
(residues 411-630) domain cDNAs were constructed using the GST
fusion vector pGEX-KN (25). A single colony of BL21(DE3)-pLysS cells
transformed with the amino- or carboxyl-terminal plasmid was grown in
Luria broth (LB, 170 mM NaCl, pH 7.5, 1% tryptone, 0.5%
yeast extract) containing 20 µg/ml carbenicillin (Life Technologies,
Inc.) and then used to seed a 500-ml culture. After growing to an
optical density of 0.6-0.8 (A600) the culture was centrifuged (Beckman model J2-21M, 1000 × g, 15 min, 4 °C). The cell pellet was resuspended in 500 ml of LB with
carbenicillin. The bacteria were induced by incubation at room
temperature with 200 µM isopropyl
-D-thiogalactopyranoside (Sigma) for 4 h and were
harvested by centrifugation.
The methods for protein purification and solubilization were modified
from those previously published (26, 27). The cells were resuspended
and incubated in Tris buffer 1 (50 mM Tris-HCl, pH 8.0, 2 mM EDTA, 10 µg/ml pepstatin, 10 µg/ml leupeptin, 100 µM phenylmethylsulfonyl fluoride) containing 10 mM -mercaptoethanol and 100 µg/ml lysozyme (Sigma) for
15 min at 30 °C. Following solubilization with 1.5%
N-laurylsarcosine, the lysate was incubated with 20 µg/ml
DNase I (Roche Molecular Biochemicals) and 10 mM MgCl2. The lysate was then centrifuged (Sorvall RT 6000B,
1000 × g, 15 min, 4 °C) and adjusted to a 2%
Triton X-100 concentration.
The GST fusion proteins were purified using glutathione affinity
absorption. Glutathione-agarose beads were washed, resuspended in Tris
buffer 1, and then incubated with the lysate for 1 h at 4 °C.
The beads were washed 3 times with Tris buffer 1 by repeated centrifugation (Sorvall, 100 × g, 5 min, 4 °C).
After the final wash, the bead preparation was resuspended in Tris
buffer 2 (50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA,
0.5 mM EGTA, 1 mM
Na4P2O7, 10 µg/ml aprotinin, 10 µg/ml leupeptin). The recombinant proteins were left on the beads for
subsequent experiments.
PKA Phosphorylation of Kv4.2 Amino- and Carboxyl-terminal GST
Fusion Proteins--
Kv4.2 amino- or carboxyl-terminal GST fusion
proteins were incubated for 30 min at 37 °C in reaction mixtures (25 µl) containing 70 ng of the catalytic subunit of PKA, Tris buffer 2, and ATP mix 1 (100 µM ATP, 100 mM
MgCl2, and 10 µCi [ -32P]ATP). Reactions
were stopped by boiling for 5 min with sample buffer (30 mM
Tris-HCl, pH 6.8, 200 mM DTT, 40% glycerol, 8% SDS, 0.04 mg/ml bromphenol blue). The GST fusion proteins were separated by
SDS-PAGE (12.5%) and visualized by Coomassie Blue staining. Phosphopeptides were identified by autoradiography. As a control parallel reactions were performed for GST with and without PKA and ATP
mix 1. A time course of PKA phosphorylation of the amino- and
carboxyl-terminal proteins was performed.
Phosphopeptide Mapping--
PKA phosphorylation reactions were
performed as described previously except for the following
modifications: a preparative scale (reaction volume of 300-400 µl)
was used, specific activity was increased (20 µCi of
-32P/25-µl reaction volume and 50 µM
ATP), and the incubation period was increased to 90 min based on the
time course of PKA phosphorylation of the fusion proteins. The
phosphorylated amino- or carboxyl-terminal GST fusion proteins were
separated by SDS-PAGE (12.5%). Following Coomassie Blue staining of
the gels, the bands corresponding to the amino- or carboxyl-terminal
fusion proteins were excised, and an in-gel digestion with trypsin or
Lys-C was performed as described previously with minor modifications
(28). Following extraction from the gel, the peptides were separated
using reverse phase HPLC (high pressure liquid chromatography) with
absorption monitoring at 214, 254, and 280 nm. Counts/min (cpm) in each
HPLC fraction was measured as Cerenkov radiation. Phosphopeptides
identified as HPLC fractions containing high radioactivity were applied
to Sequelon arylamine membranes (Millipore Corp.) essentially as described by the manufacturer. After drying, the membrane was rinsed
two times sequentially with 10 ml of methanol, then with water, and
finally with 5 ml of 10% trifluoroacetic acid, 50% acetonitrile in
water. The membrane was air-dried, cut into pieces with a scalpel
blade, and inserted in a BLOTT cartridge and sequenced in an Applied
Biosystems model 477A Protein Sequencer with an in-line 120A
PTH-Analyzer (Applied Biosystems, Foster City, CA) using optimized
cycles. Instead of butyl chloride, 90% methanol containing phosphoric
acid (15 µl/100 ml) was used to extract the cleaved amino acids.
After conversion, 50% of the sample was transferred to the HPLC for
phenylthiohydantoin-derivative identification, and the other 50% was
collected in the instrument fraction collector for determination of
radioactivity by scintillation counting.
Kinetic Characterization of the Kv4.2 Amino- and
Carboxyl-terminal PKA Sites--
Peptides were synthesized in the
Protein Chemistry Core Laboratory (Baylor College of Medicine) which
contained the Kv4.2 amino- and carboxyl-terminal phosphorylation sites.
The synthetic peptides (NT-(32-44)) and (CT-(546-558)) had a total of
14 amino acid residues corresponding to Kv4.2 channel residues 32-44
on the amino terminus and residues 546-558 on the carboxyl terminus, respectively. The phosphorylation site was located in the middle (amino
acid number 7) of the peptide, and a cysteine residue was located at
the carboxyl terminus (amino acid number 14) of each peptide (Figs.
7A and 8A).
In the kinase assays used for kinetic characterization of the PKA
phosphorylation sites, the reaction mixture (50 µl) contained Tris
buffer 2, 70 ng of the catalytic subunit of PKA, and the NT-(32-44) or
CT-(546-558) synthetic peptides. All of the kinase assays were started
by the addition of the ATP mix 2 (100 µM ATP, 100 mM MgCl2, 5 µCi of
[ -32P]ATP) and were incubated at 25 °C. The
reactions were stopped by spotting duplicate 20-µl aliquots of the
reaction mixture onto Whatman 81 phosphocellulose filter papers and
washing in 75 mM H3PO4. After a
last wash in 99% methanol, the papers were dried, immersed in
Aquasol-2, and counted. For each experimental condition, counts
obtained from a reaction without substrate peptide were subtracted. The
assays used to determine Km and
Vmax were linear with respect to time and linear
with added kinase (PKA), and less than 10% of the peptide substrate
was converted to product. To obtain the concentration curve for each of
the peptides, peptide concentrations ranging from 5 to 400 µM were used. As a control parallel reactions were
included using the PKA substrate Kemptide.
The activated catalytic domain of protein kinase C (PKC), catalytic
domain of calcium/calmodulin-dependent protein kinase II
(CaMKII), and activated mitogen-activated protein kinase (MAPK) were
assayed for phosphorylation of the NT-(32-44) or CT-(546-558) substrates. Known substrates for each of the kinases were used as
positive controls as follows: PKC, NG-(28-43), a synthetic peptide
analogue of a fragment of neurogranin (29); CaMKII, Autocamtide-2; and
MAPK, myelin basic protein. The methods used for the kinase assays were
as described above with the following modifications: the PKC reaction
contained 0.1 µg of PKC; the CaMKII reaction contained 2 µg of
CaMKII, reaction buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.5 mM DTT, 0.1 mM
Na2EDTA), and 2.4 mM calmodulin; and the MAPK
reaction mixture had 0.5 µg of activated MAPK and reaction buffer (25 mM Hepes, pH 7.5, 10 mM magnesium acetate, 50 µM ATP).
Antibody Characterization--
The synthetic peptides
NT-(32-44) or CT-(546-558) containing the phosphorylated
Thr38 and Ser552 PKA sites were coupled to
keyhole limpet hemocyanin and injected into rabbits. The antisera were
screened by Western blotting using the phosphorylated and
unphosphorylated ovalbumin-coupled synthetic peptides and GST fusion
proteins. The antisera were affinity purified against the NT-(32-44)
or CT-(546-558) synthetic peptides using Hi-trap columns (Amersham
Pharmacia Biotech).
The purified antisera were used to examine PKA recognition of the
phosphorylation sites on the amino and carboxyl termini when Kv4.2 was
expressed as an EGFP fusion protein in COS-7 cells. The FuGene 6 Transfection Reagent was used for COS-7 cells transfections with
plasmid DNAs (0.1-2.0 µg/µl), using cytomegalovirus promoters expressing EGFP (enhanced green fluorescent protein) (30), EGFP-Kv4.2 fusion protein, or Kv4.2 alone. The EGFP-Kv4.2 fusion protein was made
by introduction of a synthetic NotI site in the C terminus of EGFP. The amino terminus of Kv4.2 was adapted by PCR to clone in-frame with EGFP at the NotI site just before the
initiation Met codon. The EGFP-Kv4.2 expression construct resulted in
considerably higher levels of Kv4.2 protein expression compared with
the Kv4.2 non-fusion construct, for unknown reasons, and therefore was
the construct of choice for our cellular phosphorylation studies.
Transfected cells were grown on 35-mm plates to a 2 × 105 cell density. The cell cultures were then incubated for
10 min with phosphate-buffered saline (PBS) (pH 7.5, 137 mM
NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM
KH2PO4) containing either 50 µM
forskolin and 75 µM RO126 in Me2SO or
Me2SO alone (vehicle control). The cells were then
harvested and centrifuged. The cell pellet was resuspended in 10% SDS
with 100 mM DTT, 10 µg/ml pepstatin, 10 µg/ml
aprotinin, 10 µg/ml leupeptin, 100 µM
phenylmethylsulfonyl fluoride. Sample buffer was then added, and the
samples were loaded on a SDS-PAGE gel (10%) for Western blotting.
Three antibodies were used for the Western blots as follows: the
phospho-selective amino-terminal antibody, 2) the phospho-selective
carboxyl-terminal antibody, and 3) the general carboxyl-terminal
antibody (not phospho-selective). The third antibody was generated by
injection of the carboxyl-terminal fusion protein construct of Kv4.2
and characterized in the laboratory of P. J. Pfaffinger.
Immunoreactivity was measured using densitometry (NIH Image).
Densitometry data were analyzed with a paired Student's t test.
In the final series of experiments the amino- and carboxyl-terminal
phospho-selective antibodies were used to evaluate modulation of PKA
phosphorylation of Kv4.2 in hippocampal area CA1. Transverse hippocampal slices were prepared using the methodology of Roberson et al. (31). After the slices had been maintained for 45-60 min in artificial cerebrospinal fluid (32 °C), 50 µM
forskolin and 75 µM RO126 in Me2SO or
Me2SO alone (vehicle control) was applied for 10 min. The
methodology of Roberson et al. (31) was used for
microdissection, storage, and sonication of the hippocampal CA1
subfields. The CA1 sonicates were centrifuged (Beckman, 100,000 × g, 20 min, 4 °C), and the pellet was resuspended as
described for the COS-7 cells except that 200 mM DTT was
used in the 10% SDS solution and in the sample buffer. The CA1
membrane proteins were then used for Western blotting with the amino-
and carboxyl-terminal phospho-selective antibodies. The entire sample
from one CA1 subregion was loaded per lane.
Data Analysis--
The GraphPad Prism software package was used
for statistical analysis of the data. Error bars represent S.E.
Materials--
The catalytic subunit of PKA, Kemptide, myelin
basic protein, and forskolin were obtained from Sigma. The catalytic
subunit of PKC (rat brain) and Autocamtide-2 were obtained from
Calbiochem. CaMKII (truncated, 1-325 amino acids) and calmodulin were
obtained from New England Biolabs. Activated MAPK was obtained from
Stratagene. Glutathione-agarose beads and [ -32P]ATP
were obtained from Amersham Pharmacia Biotech. The FuGene 6 Transfection Reagent was obtained from Roche Molecular Biochemicals. The EGFP construct was obtained from CLONTECH. The
anti-Kv4.2 antibody was obtained from Alomone Labs. This antibody was
made against a peptide corresponding to Kv4.2 residues 454-469.
Synthetic Peptides--
The NT-(32-44) or CT-(546-558)
peptides were synthesized in the Protein Core Chemistry Laboratory at
Baylor College of Medicine using an Applied Biosystems model 430A
peptide synthesizer and purified by reverse phase HPLC. Protein
concentrations and amino acid compositions were determined by amino
acid analysis.
Generation of Antisera--
The NT-(32-44) or CT-(546-558)
peptides were coupled to activated keyhole limpet hemocyanin. Albino
New Zealand rabbits were injected with an initial inoculation of 100 µg of antigen in Titremax adjuvant followed by four 50-µg boosts
according to the Cocalicao Biological Labs protocol. Test bleeds were
performed after the first 2 boosts.
 |
RESULTS |
Kv4.2 Amino- and Carboxyl-terminal Domains Are Substrates for
PKA--
Inspection of the amino acid sequence of Kv4.2 revealed a
number of candidate PKA phosphorylation sites (Fig.
1). We deemed the most likely
possibilities to be two sites within the amino-terminal and seven
within the carboxyl-terminal cytoplasmic domains. These sites were of
particular interest because previous studies have demonstrated
Shaker-type K+ channel regulation by protein kinase
phosphorylation of the cytoplasmic amino- and carboxyl-terminal regions
(32) and also because these sites are in the putative intracellular
domains accessible to protein kinases.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 1.
The putative Shal-type K+ channel
structure and Kv4.2 amino acid sequence. A, a schematic
drawing of a mammalian potassium channel illustrates amino- and
carboxyl-terminal cytoplasmic domains, six transmembrane domains, and
extracellular domains. Regions within the cytoplasmic domains of the
channel containing candidate PKA phosphorylation sites are marked by an
*. B, inspection of the amino acid sequence of the
Shal-type potassium channel, Kv4.2, reveals a number of candidate
consensus PKA phosphorylation sequences (bold). There are
two candidate PKA sites on the amino-terminal domain, one in the fifth
transmembrane domain, two located extracellularly, and 7 on the
carboxyl-terminal domain.
|
|
We first tested the hypothesis that the amino- and carboxyl-terminal
cytoplasmic domains of Kv4.2 are PKA substrates. Recombinant protein
constructs (GST fusion proteins) of the amino and carboxyl termini of
Kv4.2 were phosphorylated with PKA in vitro. Reaction products were separated with SDS-PAGE. Bands corresponding to the
amino- and carboxyl-terminal constructs were identified with Coomassie
Blue staining (Fig. 2). Autoradiography
revealed 32P labeling in both the amino- and
carboxyl-terminal recombinant proteins (Fig. 2) and confirmed that GST
was not phosphorylated by PKA (not shown). Based on these findings, we
conclude that both of the recombinant proteins corresponding to the
amino- and carboxyl-terminal cytoplasmic domains of Kv4.2 are
substrates for PKA.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Phosphorylation of Kv4.2 amino-terminal and
carboxyl-terminal GST fusion proteins by PKA in
vitro. Purified recombinant GST fusion proteins
corresponding to the amino-terminal (NT) and
carboxyl-terminal (CT) cytoplasmic domains of Kv4.2 were
reacted with PKA in vitro. Reaction products were separated
using SDS-PAGE. Coomassie Blue staining and autoradiography were
performed to identify the phosphopeptides. A, the Coomassie
Blue-stained gel (Coomassie) shows a 40-kDa peptide
corresponding to the amino-terminal construct. The autoradiogram
(Autorad) to the right demonstrates
32P incorporation in this region, indicating
phosphorylation of the amino-terminal construct. B, a 54-kDa
peptide is seen on the Coomassie Blue-stained gel corresponding to the
carboxyl-terminal construct. Autoradiography of the gel demonstrates
32P incorporation in this region, indicating
phosphorylation of the carboxyl-terminal construct.
|
|
Identification of the PKA Phosphorylation Sites on the Kv4.2 Amino-
and Carboxyl-terminal Cytoplasmic Domains--
Our next goal was to
identify the PKA phosphorylation sites on the cytoplasmic domains of
Kv4.2. The GST fusion proteins were utilized for these experiments
because we could express large amounts of the proteins for use in
phosphopeptide mapping and sequencing. First, the fusion proteins were
incubated with PKA and 32P in vitro, separated
with SDS-PAGE, and then identified by Coomassie Blue staining. Bands
corresponding to the amino- and carboxyl-terminal constructs were
excised, eluted, and proteolyzed. We performed phosphopeptide mapping
and amino acid sequencing of the phosphorylated Kv4.2 amino- and
carboxyl-terminal fusion proteins.
A single PKA phosphorylation site was identified in the amino-terminal
cytoplasmic domain. The phosphopeptide map for the amino-terminal
construct demonstrated a single peak in radioactivity in HPLC fraction
48 (Fig. 3B) corresponding to
a single HPLC absorbance peak (Fig. 3A). HPLC fraction 48 was sequenced using automated Edman degradation, and the amount of
radioactivity released with each sequencing cycle was measured (Fig.
4B). This revealed a single
phosphopeptide corresponding to Kv4.2 amino-terminal residues 36-51,
with one phosphorylation site at Thr38 (Fig.
4A).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Phosphopeptide mapping of the tryptic
amino-terminal fragments. A, phosphopeptide mapping was
performed following PKA phosphorylation in vitro of the
recombinant protein representing the Kv4.2 amino-terminal cytoplasmic
domain. The arrow indicates the absorbance peak
corresponding to the HPLC fraction with the peak in radioactivity
(fraction 48 shown below). In the HPLC trace, the y axis
represents absorbance units (AU) at 214 nm and the
x axis represents time in minutes of fraction collection.
B, the radioactivity plot illustrates a single peak in
radioactivity in HPLC fraction 48. In the radioactivity plot,
32P counts/min (CPM) measured as Cerenkov
radiation are represented on the y axis and the fraction
numbers are represented on the x axis.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Identification of the PKA phosphorylation
site on the amino-terminal cytoplasmic domain of Kv4.2.
A, the sequence of the phosphopeptide in HPLC fraction 48 that was determined by automated amino acid sequencing corresponded to
amino acids 36-51 within the amino-terminal domain of Kv4.2. The
phosphorylated amino acid, Thr38, is marked by an
asterisk. B, the radioactivity released with each
sequencing cycle was measured. There is a peak in sequence cycle number
3 indicating that Thr38 is the phosphorylated amino acid.
The y axis represents the 32P counts/min
(CPM) and the x axis represents the sequencing
cycle number.
|
|
Confirmation of a single phosphorylation site within the Kv4.2 amino
terminus was obtained by performing PKA phosphorylation experiments on
recombinant proteins representing two aspects of the Kv4.2 amino
terminus: the first representing the entire amino terminus (amino acids
residues 1-133) and the second a truncated amino-terminal construct
(amino acid residues 41-133) lacking the phosphorylation site
identified by Edman degradation. The truncated construct demonstrated
no 32P labeling (not shown) narrowing the possibilities for
candidate PKA phosphorylation sites to Thr38 on the amino
terminus. These studies together with the sequencing data suggest that
we did not miss any PKA sites on the amino-terminal cytoplasmic domains
of Kv4.2.
We found that there is also a single PKA phosphorylation site on the
carboxyl-terminal cytoplasmic domain of Kv4.2. Phosphopeptide mapping
of the carboxyl-terminal construct following 32P labeling
and trypsin digestion demonstrated a peak of radioactivity (Fig.
5B) that corresponded to a
single HPLC absorbance peak (Fig. 5A). The HPLC fractions
were pooled and sequenced, and the amount of radioactivity released
with each sequencing cycle was measured (Fig.
6B). A single phosphopeptide
was identified corresponding to residues 551-561 within the Kv4.2
sequence with phosphorylation of Ser552 (Fig.
6A).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Phosphopeptide mapping of the tryptic
carboxyl-terminal fragments. A, the recombinant protein
representing the Kv4.2 carboxyl-terminal cytoplasmic domain was
phosphorylated with PKA in vitro. Peaks in
radioactivity were present in three HPLC fractions (see below) that
corresponded to a single absorbance peak (marked by an
arrow). In the HPLC trace, the y axis represents
absorbance units (AU) at 214 nm, and the x axis
represents time in min of fraction collection. B, peaks in
radioactivity were seen in HPLC fractions 46-48. These peaks
corresponded to a single peak on the HPLC trace. In the radioactivity
plot, the 32P counts/min (CPM) measured as
Cerenkov radiation are represented on the y axis, and the
fraction numbers are represented on the x axis.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 6.
Identification of the PKA phosphorylation
site on the carboxyl-terminal cytoplasmic domain of Kv4.2.
A, HPLC fractions 46-48 were pooled and then sequenced
using automated amino acid sequencing. The phosphopeptide sequence that
was obtained corresponded to amino acids 551-561 of the
carboxyl-terminal domain of Kv4.2. The phosphorylated amino acid
residue, Ser552, is marked by an asterisk.
B, the radioactivity released with each sequencing cycle was
measured. The radioactivity peak in sequence cycle number 2 indicates
that Ser552 is the phosphorylated amino acid. The
y axis represents the 32P counts/min
(CPM), and the x axis represents the sequencing
cycle number.
|
|
To ensure that we had not missed any PKA phosphorylation sites and to
confirm the sequencing results from the carboxyl-terminal peptide, a
second digest was performed using Lys-C. Phosphopeptide mapping
following Lys-C digestion of the carboxyl-terminal construct resulted
in peak radioactivity in 5 consecutive HPLC fractions (not shown).
Amino acid sequencing of each of these fractions revealed a single
phosphopeptide containing the phosphorylated amino acid residue
corresponding to Ser552 of Kv4.2. These results confirm our
earlier findings of a single PKA phosphorylation site on the
carboxyl-terminal cytoplasmic domain of Kv4.2.
Based on these phosphopeptide mapping and amino acid sequencing
results, the PKA phosphorylation sites on the amino- and
carboxyl-terminal cytoplasmic domains of Kv4.2 have been identified as
Thr38 and Ser552. Each of the identified
phosphorylated residues lies within a putative consensus PKA
phosphorylation site within the Kv4.2 amino acid sequence.
Kv4.2 Amino- and Carboxyl-terminal Synthetic Peptides Are
Efficacious Substrates for PKA--
One caveat of this approach to the
identification of PKA phosphorylation sites is that these sites may not
be biologically relevant. One way to test this is to determine the
efficiency with which these sites on the amino- and carboxyl termini of
Kv4.2 are phosphorylated by PKA in vitro. In order to do
this, we synthesized two peptides corresponding to residues 32-44 on
the amino terminus (NT-(32-44)) and residues 546-558 on the carboxyl
terminus (CT-(546-558)) (Figs.
7A and
8A, respectively). Kemptide, a
well characterized PKA substrate, was used in parallel assays under the
same conditions. The synthetic peptides and Kemptide were subjected to
kinetic characterization. Kinetic characterization of Kemptide served as a standard for comparison to the results obtained with the synthetic
peptides.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Concentration curve for PKA phosphorylation
of the Kv4.2 amino-terminal site. A, kinetic
characterization was performed using a synthetic peptide (NT-(32-44))
containing the the amino-terminal PKA phosphorylation site.
B, the concentration curve for PKA phosphorylation of
NT-(32-44) at concentrations ranging from 5 to 300 µM is
shown. Each point is the mean of two determinations assayed in
duplicate. Inset, Lineweaver-Burk plot of the data.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Concentration curve for PKA phosphorylation
of the Kv4.2 carboxyl-terminal domain. A, kinetic
characterization of the carboxyl-terminal site was performed using a
synthetic peptide (CT-(546-558)) containing the carboxyl-terminal PKA
phosphorylation site. B, the concentration curve for PKA
phosphorylation of CT-(546-558) at concentrations ranging from 5 to
400 µM is shown. Each point is the mean of two
determinations assayed in duplicate. Inset, Lineweaver-Burk
plot of these data.
|
|
PKA phosphorylation of the NT-(32-44) synthetic peptide demonstrated
substrate concentration dependence (Fig. 7B).
Lineweaver-Burk analysis of the phosphorylation data using peptide
concentrations ranging from 5 to 300 µM resulted in a
linear double-reciprocal plot (Fig. 7B, inset). However, at
higher concentrations (400 µM) the NT-(32-44) peptide
exhibited some substrate inhibition. Consequently, the
Km and Vmax from these data
should be considered as estimates. The value for Km
was estimated to be 294 µM, and the maximal velocity
(Vmax) of PKA phosphorylation of the
amino-terminal peptide was estimated to be 7.7 µmol/min/mg.
The CT-(546-558) synthetic peptide was also phosphorylated by PKA in a
substrate concentration-dependent manner that was
consistent with Michaelis-Menten kinetics (Fig. 8B). A
linear double-reciprocal plot resulted from Lineweaver-Burk analysis of
the phosphorylation data using substrate concentrations ranging from 5 to 400 µM (Fig. 8B, inset). From
these data, the apparent Km value for the
CT-(546-558) peptide is 133.7 µM. The calculated
Vmax value for PKA phosphorylation of the
CT-(546-558) peptide is 54.1 µmol/min/mg. The Km
value for each of the synthetic peptides is in the range of those
published and obtained in parallel kinase assays performed here with a
well established PKA substrate, Kemptide (Km = 16 µM and Vmax = 20.2 µmol/min/mg,
30 °C) (33). These results suggest that both of the peptides are
good substrates for PKA with the carboxyl-terminal peptide being more
efficacious than the amino-terminal peptide. Whereas these data were
obtained by phosphorylation of the sites in vitro, our
findings suggest that there may be a preference for Ser552
over Thr38 when phosphorylated within the native channel
in vivo.
In some cases multiple protein kinases have been shown to converge on a
single phosphorylation site. We tested whether the synthetic peptides
were substrates for PKC, CaMKII, and MAPK (Fig. 9). The NT-(32-44) and CT-(546-558)
synthetic peptides do not have any proline residues suggesting that
these peptides are not MAPK substrates, and the data obtained from MAPK
incubation with the synthetic peptides support this conclusion. We have
previously shown that PKC and CaMKII phosphorylate the carboxyl
terminus but not the amino terminus of Kv4.2 (34, 35). The results obtained here suggest that neither the CT nor the NT PKA sites are
efficacious substrates for these kinases as there was only modest
phosphorylation of the NT-(32-44) or CT-(546-558) synthetic peptides
by PKC and CaMKII in comparison to known PKC or CaMKII substrates (Fig.
9).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 9.
PKC, CaMKII, and MAPK do not phosphorylate
the amino- and carboxyl-terminal synthetic peptides. Saturating
concentrations of the NT-(32-44) (300 µM) and the
CT-(546-558) (400 µM) synthetic peptides were incubated
with PKA, PKC, CaMKII, or MAPK and [ -32P]ATP in
vitro. Parallel reactions were performed using known substrates
(control substrate) for each of the kinases: Kemptide (KT)
for PKA, NG-(28-43) (NG, neurogranin) for PKC,
Autocamtide-2 (Autocam) for CaMKII, and myelin basic protein
(MBP) for MAPK. All reactions were performed in duplicate,
and an average was taken. Phosphorylation of the NT-(32-44) and
CT-(546-558) synthetic peptides is shown as a percentage of the
control substrate phosphorylation for each kinase. Although there is
minimal 32P incorporation with PKC and CaMKII incubation
with the synthetic peptides, it is less than 13% of that seen with
neurogranin or Autocamtide-2. Comparison to the 32P
incorporation in the NT-(32-44) and CT-(546-558) synthetic peptides
by PKA demonstrates that these sites are much better substrates for
PKA.
|
|
Phospho-site-selective Antibodies for the Amino- and
Carboxyl-terminal PKA Phosphorylation Sites on Kv4.2--
As a final
test of PKA phosphorylation at Thr38 and Ser552
on Kv4.2 we generated phospho-site-selective antibodies. The affinity purified antibodies were screened with Western blotting against the
unphosphorylated and phosphorylated ovalbumin-coupled NT-(32-44) or
CT-(546-558) synthetic peptides. There was selective immunoreactivity to only the phosphorylated synthetic peptides that were blocked by
preincubation of the antibody with the antigen (Fig.
10). We next sought to determine
whether the antisera recognized the PKA phosphorylation sites in the
GST fusion proteins. Western blotting revealed that the antisera
selectively recognized the phosphorylated amino- and carboxyl-terminal
fusion protein constructs (Fig. 11). This immunoreactivity was blocked by preincubation with the antigen (not shown). These data confirm the sequencing results obtained with
PKA phosphorylation of the fusion proteins. Furthermore, from these
experiments we conclude that the amino- and carboxyl-terminal antibodies are phospho-selective.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 10.
Phospho-selectivity of the antibodies
developed against the PKA phosphorylation sites identified on
Kv4.2. Antisera were generated using the NT-(32-44) and
CT-(546-558) synthetic peptides containing the phosphorylated amino-
or carboxyl-terminal PKA phosphorylation sites and screened with
Western blotting. A, Western blotting was performed using
the unphospho- and phospho-NT-(32-44) synthetic (NT)
peptides coupled to albumin. There is selective immunoreactivity of the
amino-terminal antibody (Ab) for only the NT synthetic
phosphopeptide (left panel). This immunoreactivity is
blocked by preincubation with the NT phospho-peptide (Ag)
(right panel). B, similar results were obtained
from Western blotting of the ovalbumin-coupled unphospho- and
phospho-CT-(546-558) synthetic (CT) peptides using the
carboxyl-terminal antibody. The phospho-selectivity is blocked by
preincubation with the phospho-CT peptide (Ag). From these
findings, we conclude that both antibodies developed against the Kv4.2
amino- and carboxyl-terminal PKA phosphorylation sites are
phospho-selective.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 11.
Detection of the phosphorylated GST fusion
proteins using the phospho-selective antibodies. The Kv4.2 amino-
and carboxyl-terminal (NT and CT) recombinant GST
fusion proteins were used to characterize further the
phospho-selectivity of the antibodies (Ab). A, in
this immunoblot, the NT antibody recognizes phosphorylated NT fusion
protein (+PKA) but not the unphosphorylated fusion protein
( PKA). B, similar results were obtained using
the CT antibody. The immunoreactivity shown in A and
B is blocked by preincubation with the antigen (not shown).
We conclude from these studies that each of the antibodies demonstrates
selective immunoreactivity to the phosphorylated fusion protein
construct.
|
|
Kv4.2 Phosphorylation by Endogenous PKA in the Intact
Cell--
The goal of this series of experiments was to investigate
the phosphorylation of Kv4.2 by PKA in the intact cell. Kv4.2 was expressed as an EGFP fusion protein construct in COS-7 cells. Following
expression of EGPF-Kv4.2 in COS-7 cells, green fluorescence was evident
on both intracellular and plasma membranes. Forskolin was applied to
the cell cultures for activation of the endogenous cAMP cascade.
Examination of green fluorescence after forskolin stimulation revealed
no obvious changes in EGFP-Kv4.2 protein levels or subcellular
distribution. Western blotting using the phospho-selective amino- and
carboxyl-terminal antibodies and the non-phospho-selective
carboxyl-terminal antibody was then performed (Figs.
12A and
13A, respectively). All of
the antisera recognized the same band of immunoreactivity at the
appropriate molecular weight for the EGFP-Kv4.2 fusion protein (97 kDa). Densitometric analysis demonstrated a significant increase in
immunoreactivity with the amino- and carboxyl-terminal antibodies
following forskolin stimulation (NT, 361.3 ± 7.6% of control;
CT, 286.2 ± 60.0% of control, n = 3, p < 0.05) (Figs. 12B and 13B,
respectively). There was no significant increase in immunoreactivity in
parallel blots using the general carboxyl-terminal antibody following
forskolin stimulation, indicating that this manipulation does not
result in a change in protein expression (Figs. 12A and
13A). Thus we conclude that Thr38 and
Ser552 within Kv4.2 are phosphorylated by endogenous PKA in
the intact cell.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 12.
Endogenous PKA recognizes the amino-terminal
PKA phosphorylation site within Kv4.2 in the intact cell. COS-7
cells transiently expressing EGFP or EGFP-rKv4.2 were stimulated with
50 µM forskolin to activate PKA. A, Western
blotting was performed using two antibodies to Kv4.2 as follows: the
phospho-selective antibody to the phosphorylated amino-terminal PKA
site (Anti-PKA NT Site) (left panel) and a
general antibody that recognizes the carboxyl terminus
(Anti-total Kv4.2) (right panel). The
immunoreactivity at 97 kDa that is seen with both antibodies
corresponds to the EGFP-Kv4.2 fusion protein construct. By using the
anti-PKA NT antibody, a significant increase in immunoreactivity is
seen with forskolin (Forsk) stimulation compared with
control (vehicle-treated) cultures (left panel). With the
anti-total Kv4.2 antibody we were able to determine that there were
good expression levels of the EGFP-Kv4.2 construct and that there was
no significant change in protein expression levels with forskolin
stimulation (right panel). B, the above change in
immunoreactivity with forskolin stimulation compared with
vehicle-treated cultures was evaluated using densitometry. There is a
significant increase in immunoreactivity with forskolin stimulation
using the anti-PKA NT antibody compared with control levels (361.3 ± 7.6% of control, n = 3, p < 0.05).
There is no significant change in immunoreactivity using the anti-total
Kv4.2 antibody in the stimulated compared with control cultures
(99.4 ± 8.9% of control, n = 3). From these
findings, we conclude that the amino-terminal phosphorylation site on
Kv4.2 is recognized by endogenous PKA in intact cells.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 13.
Endogenous PKA recognizes the
carboxyl-terminal PKA phosphorylation site on Kv4.2 in the intact
cell. COS-7 cells transiently expressing EGFP or EGFP-rKv4.2 were
stimulated with 50 µM forskolin (Forsk) to
activate PKA. A, Western blotting was performed using two
antibodies to the carboxyl terminus as follows: the phospho-selective
antibody to the phosphorylated carboxyl-terminal PKA site
(Anti-PKA CT Site) (left panel) and an antibody
that recognizes the carboxyl terminus of Kv4.2 (Anti-total
Kv4.2) (right panel). The immunoreactivity at 97 kDa
that is seen with both antibodies corresponds to the EGFP-Kv4.2 fusion
protein construct. By using the anti-PKA CT antibody, a significant
increase in immunoreactivity is seen with forskolin stimulation
compared with control (vehicle-treated) cultures (left
panel). By using the anti-total Kv4.2 antibody we saw good
expression levels of the EGFP-Kv4.2 construct and no significant change
in expression levels with forskolin stimulation (right
panel). B, the increase in immunoreactivity with
forskolin stimulation compared with vehicle-treated cultures was
evaluated using densitometry. There is a significant increase in
immunoreactivity using the anti-PKA CT antibody with forskolin
stimulation compared with control levels (286.2 ± 60.0% of
control, n = 3, p < 0.5). There is no
significant change in immunoreactivity using the anti-total Kv4.2
antibody in the stimulated compared with control conditions (110 ± 7.0% of control, n = 3). Based on these studies, we
conclude that the carboxyl-terminal phosphorylation site on Kv4.2 is
recognized by endogenous PKA in intact cells.
|
|
Modulation of PKA Phosphorylation of Kv4.2 in Hippocampal Area
CA1--
In the final series of experiments we evaluated the effects
of forskolin stimulation on PKA phosphorylation of Kv4.2 in hippocampal area CA1 using the phospho-selective antibodies. Immunoblots probed with the amino-terminal antibody demonstrate very low basal
phosphorylation of Kv4.2 at the amino-terminal PKA site compared with a
significant increase in phosphorylation at this site following brief
(10 min) forskolin stimulation (440.5 ± 15.6% of control,
n = 3, p < 0.05) (Fig.
14A). The immunoreactivity
observed at 70 kDa (Fig. 14A) is blocked by preincubation of
the antibody with the amino-terminal phosphopeptide against which the
antibody was made (not shown). Immunoblots probed with the
carboxyl-terminal antibody demonstrate minimal basal immunoreactivity
that is significantly increased following forskolin stimulation
(333.4 ± 47.2% of control, n = 3, p < 0.01) (Fig. 14B). Preincubation with
the carboxyl-terminal synthetic phosphopeptide also blocked this
immunoreactivity (not shown). The 70-kDa band appears to be bona
fide Kv4.2 as this protein is also recognized by a commercially
available anti-Kv4.2 antibody (Alomone Labs) and by several other
anti-Kv4.2 antisera we have generated (not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 14.
Modulation of PKA phosphorylation of Kv4.2
in hippocampal area CA1. Representative Western blots of CA1
membrane proteins (1 CA1/lane) were probed with the Kv4.2 PKA site
antibodies following brief stimulation with 50 µM
forskolin (FSK) to activate PKA versus
Me2SO vehicle (CTL). A, Western
blotting with the phospho-selective antibody to the phosphorylated
amino-terminal PKA site (Anti-PKA NT Site) is shown in the
upper panel. Densitometry of the 70-kDa band corresponding
to Kv4.2 shows that there is a significant increase in immunoreactivity
following brief (10 min) forskolin stimulation (FSK)
compared with low levels of immunoreactivity under basal conditions
(CTL) (forskolin = 440.5 ± 15.6% of control,
n = 3, p < 0.05). The immunoreactivity
observed at 70 kDa (A) is blocked by preincubation of
Anti-PKA NT Site with the amino-terminal phospho-peptide
against which the antibody was raised (not shown). B,
Western blotting using the phospho-selective antibody to the
phosphorylated carboxyl-terminal PKA site (Anti-PKA CT Site)
is shown in the upper panel. Densitometry of the 70-kDa band
reveals a significant increase in immunoreactivity with forskolin
stimulation (FSK) compared with basal conditions
(CTL) (333.4 ± 47.2% of control, n = 3, p < 0.01) (B). Preincubation with the
carboxyl-terminal synthetic phosphopeptide blocked this
immunoreactivity (not shown). The 70-kDa band is also recognized by a
commercially available anti-Kv4.2 antibody (Alomone Labs) and by
several other anti-Kv4.2 antisera we have generated (not shown). From
these data we conclude that, in the hippocampal CA1 subregion, there is
modulation of PKA phosphorylation within the cytoplasmic domains of
Kv4.2 on Thr38 and Ser552.
|
|
From these studies we conclude that, in the hippocampal CA1 subregion
where Kv4.2 is expressed, there is modulation of PKA phosphorylation
within the cytoplasmic domains of Kv4.2 on Thr38 and
Ser552. These data provide candidate loci for the
modulation of transient channels in CA1 of hippocampus by the cAMP cascade.
 |
DISCUSSION |
Our findings provide the initial basis for investigation of direct
regulation of Kv4.2 by PKA phosphorylation. We determined that PKA
phosphorylates the amino- and carboxyl-terminal cytoplasmic domains of
Kv4.2 in vitro. We identified a single major phosphorylation site within each of these domains corresponding to Thr38
and Ser552 within the Kv4.2 amino acid sequence. These
sequencing data were then used for generation of antisera that
selectively recognize these sites. By using these phospho-selective
antisera, we observed that the amino- and carboxyl-terminal cytoplasmic
domains of Kv4.2 are phosphorylated by endogenous PKA in the intact
cell. In the final series of experiments reported here, we used the
phospho-selective antibodies to show modulation of PKA phosphorylation
of the amino and carboxyl termini of Kv4.2 in hippocampal area CA1,
where Kv4.2 is expressed and modulated by the cAMP cascade. The
phospho-selective antisera for the PKA sites within Kv4.2 provide a
potentially powerful reagent for monitoring phosphorylation at specific
PKA sites on the native channels expressed in ventricular myocardium and hippocampus following activation of the PKA cascade.
Voltage-dependent, transient K+ channels
regulate membrane excitability in both hippocampal pyramidal neurons
and ventricular myocytes (5, 6). The preponderance of evidence
indicates Kv4.2 -subunits contribute to forming these transient
currents (3, 9). In hippocampal CA1 dendrites,
voltage-dependent, transient K+ channels
regulate both pyramidal neuron excitability and the magnitude of the
post-synaptic excitatory post-synaptic potential (5). The
electrophysiological properties of the transient K+
currents recorded in hippocampal CA1 dendrites are consistent with
those of Kv4.2, and Kv4.2 is selectively localized to this region of
hippocampus (3, 9). Of interest in the context of our findings is that
the voltage-dependent activation of the transient currents
recorded in dendrites is decreased by PKA or PKC activation (21). In
ventricular myocardium, the transient current contributes to action
potential duration and myocardial contractility, and it is thought to
be involved in cardiac pacemaker actions (6). Studies have shown that
in rat ventricular myocardium, Kv4.2 is one of the K+
channel -subunits that significantly contributes to the transient current recorded in this region of the heart (3, 11, 36). Furthermore,
there is evidence suggesting that transient currents in ventricular
myocytes are modulated by neurotransmitter systems that are coupled to
second messenger cascades (22-24). Together these data support the
hypothesis that during the regulation of hippocampal and myocardial
excitability the activity of Kv4.2 is modulated by protein kinase activation.
Protein phosphorylation is known to be an important mechanism of
regulation of K+ channel activity (37-41). There are well
documented examples of PKA or PKC phosphorylation of K+
channel -subunit domains that result in modulation of channel properties. Phosphorylation of K+ channel amino- or
carboxyl-terminal cytoplasmic domains by Ser/Thr kinases has been shown
to alter inactivation kinetics, change levels of channel expression at
the cell membrane, and modulate current amplitude (32). These findings
and the idea that the cytoplasmic domains would be accessible to
cellular kinases make it likely that these regions are sites of protein
kinase regulation of the Kv4.2 -subunit. An additional important
point is that in the K+ channel cytoplasmic domains a
divergence in homology could allow selective protein kinase regulation
of various channel subtypes. On the other hand, conservation of protein
kinase regulatory sites implies preservation of a regulatory site
across channel subtypes. The Kv4 proteins demonstrate a very high
degree of sequence homology in the regions on the six transmembrane
domains and less homology in the amino- and carboxyl-terminal
cytoplasmic domains (42-45). Interestingly, a PKA site at
Thr38 is not conserved among the Kv4 subfamily members,
whereas the site at Ser552 is conserved.
We initially focused on the identification of the sites at which PKA
phosphorylates Kv4.2; in addition, we have previously demonstrated that
PKC and CaMKII also phosphorylate the carboxyl- but not the
amino-terminal domain of Kv4.2 (35). The amino acids within the Kv4.2
sequence that are phosphorylated by PKC and CaMKII have not yet been
identified. However, our findings suggest that PKA, PKC, and CaMKII do
not converge on Ser552 as evidenced by the fact that there
is relatively low 32P incorporation into this site by PKC
or CaMKII compared with known substrates for these protein kinases or
compared with PKA phosphorylation of the site. Amino acid sequencing
experiments to identify the PKC and CaMKII sites are required to
determine conclusively if there is any overlap in the sites where these protein kinases phosphorylate Kv4.2.
In the current studies we have identified a novel approach to
ascertaining the cytoplasmic domain phosphorylation sites on K+ channels. Our experimental approach provides a paradigm
by which to study kinase phosphorylation of other K+
channels. The methodology is applicable to any channel or membrane protein with substantial cytoplasmic domains such as the amino and
carboxyl termini of other voltage-dependent K+
channels. This approach, i.e. express the carboxyl and amino termini in E. coli, identify the phosphorylation sites in
the recombinant protein, and then generate phospho-selective antisera, should be adaptable to the study of most K+ channels.
However, one caveat to our approach is the possibility of missing some
sites in the native channel. There may be phosphorylation sites in
parts of the native channel that are not present in the cytoplasmic
amino- and carboxyl-terminal domains or that are not efficacious sites
for phosphorylation in vitro.
Our methodology provides advantages over the traditional approach of
using site-directed mutagenesis for the identification of protein
kinase phosphorylation sites. Although insight into protein kinase
regulation of ion channels may be obtained through site-directed
mutagenesis, this approach may cause conformational changes and
alterations in tetramerization of -subunits, leading to problems
with the identification of physiologic phosphorylation sites. In
addition, site-directed mutagenesis does not allow for evaluation of
the phosphorylation sites in the native channel in vivo. In
contrast, our approach using phospho-selective antibodies provides a
tool for the studying phosphorylation sites within the native channel
in vivo. The phospho-selective antibodies can be used to
ascertain phosphorylation of the sites within the native channel by
endogenous protein kinases. The antibodies can also be used to evaluate
the conditions under which these sites are phosphorylated. In addition,
the subcellular distribution of phosphorylation at these sites can be
evaluated. In this manner, our approach provides a powerful tool for
the evaluation of K+ channel phosphorylation under
physiologic conditions that could significantly facilitate the
understanding of protein kinase regulation of membrane excitability.
The PKA cascade is a major site of regulation of hippocampal and
myocardial excitability. Our findings provide the first insight into a
specific molecular target, Kv4.2, for PKA in the context of regulation
of membrane excitability. Future work will allow determination of the
role of Thr38 and Ser552 phosphorylation in the
regulation of Kv4.2 channel function. The use of phospho-selective
antisera for these sites will allow quantitation of these specific
phosphorylation events in vitro and in vivo.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Cain Foundation Labs,
BCM, Feigin Center MC 3-6365, 6621 Fannin St., Houston, TX 77030. Tel.: 713-798-3107; Fax: 713-798-3946; E-mail:
aander@cns.neusc.bcm.tmc.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
PKA, cAMP-dependent protein kinase;
GST, glutathione
S-transferase;
HPLC, high pressure liquid chromatography;
PKC, protein kinase C;
CaMKII, calcium/calmodulin-dependent
protein kinase II;
DTT, dithiothreitol;
MAPK, mitogen-activated protein
kinase;
EGFP, enhanced green fluorescent protein;
PAGE, polyacrylamide
gel electrophoresis.
 |
REFERENCES |
| 1.
|
Hille, B.
(1992)
Ionic Channels of Excitable Membranes
, 2nd Ed.
, pp. 115-135, Sinauer Associates, Inc., Sunderland, MA
|
| 2.
|
Serodio, P.,
Kentros, C.,
and Rudy, B.
(1994)
J. Neurophysiol.
72,
1516-1529[Abstract/Free Full Text]
|
| 3.
|
Barry, D. M.,
Trimmer, J. S.,
Merlie, J. P.,
and Nerbonne, J. M.
(1995)
Circ. Res.
77,
361-369[Abstract/Free Full Text]
|
| 4.
|
Martina, M.,
Schultz, J. H.,
Ehmke, H.,
Monyer, H.,
and Jonas, P.
(1998)
J. Neurosci.
18,
8111-8125[Abstract/Free Full Text]
|
| 5.
|
Hoffman, D. A.,
Magee, J. C.,
Colbert, C. M.,
and Johnston, D.
(1997)
Nature
387,
869-875[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Cohen, I.,
Datyner, N.,
Gintant, G.,
and Kline, R.
(1986)
in
The Heart and Cardiovascular System
(Fozzard, H. A.
, Jennings, R. B.
, Haber, E.
, Katz, A. M.
, and Morgan, H. E., eds)
, pp. 637-670, Raven Press, Ltd., New York
|
| 7.
|
Barry, D. M.,
Xu, H.,
Schuessler, R. B.,
and Nerbonne, J. M.
(1998)
Circ. Res.
83,
560-567[Abstract/Free Full Text]
|
| 8.
|
Sheng, M.,
Tsaur, M.-L.,
Jan, Y. N.,
and Jan, L. Y.
(1992)
Neuron
9,
271-284[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Serodio, P.,
and Rudy, B.
(1998)
J. Neurophysiol.
79,
1081-1091[Abstract/Free Full Text]
|
| 10.
|
Alonso, G.,
and Widmer, H.
(1997)
Neuroscience
77,
617-621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Dixon, J. E.,
and McKinnon, D.
(1994)
Circ. Res.
75,
252-260[Abstract/Free Full Text]
|
| 12.
|
Furukawa, T.,
Myerburg, R.,
Furukawa, N.,
Bassett, A.,
and Kimura, S.
(1990)
Circ. Res.
67,
1287-1291[Abstract/Free Full Text]
|
| 13.
|
Liu, D.-W.,
Gintant, G.,
and Antzelevitch, C.
(1993)
Circ. Res.
72,
671-687[Abstract/Free Full Text]
|
| 14.
|
Levitan, I.,
and Kaczmareck, L.
(1991)
The Neuron: Cell and Molecular Biology
, Oxford University Press, New York
|
| 15.
|
Jan, L.,
and Jan, Y.
(1992)
Annu. Rev. Physiol.
54,
537-555[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Pongs, O.
(1992)
Physiol. Rev.
72 Suppl. 4,
69-88
|
| 17.
|
Chandy, K.,
and Gutman, G.
(1995)
in
Handbook of Receptors and Channels: Ligand and Voltage-gated Ion Channels
(North, R., ed)
, CRC Press, Inc., Boca Raton, FL
|
| 18.
|
Chabala, L. D.,
Bakry, N.,
and Covarrubias, M.
(1993)
J. Gen. Physiol.
102,
713-728[Abstract/Free Full Text]
|
| 19.
|
Kaczmarek, L.
(1992)
Behav. Neural Biol.
57,
263-266[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Madison, D. V.,
and Nicoll, R. A.
(1986)
J. Physiol. (Lond.)
372,
245-259[Abstract/Free Full Text]
|
| 21.
|
Hoffman, D. A.,
and Johnston, D.
(1998)
J. Neurosci.
18,
3521-3528[Abstract/Free Full Text]
|
| 22.
|
Williamson, J. R.,
and Schaffer, S.
(1976)
Recent Adv. Stud. Card. Struct. Metab.
9,
205-223[Medline]
[Order article via Infotrieve]
|
| 23.
|
Geschwind, H. J.,
Lhoste, F.,
Scriven, A. J.,
Dhainaut, J. F.,
Sabatier, C.,
and Laurent, D.
(1984)
J. Am. Coll. Cardiol.
4,
216-225[Abstract]
|
| 24.
|
Nakamura, T. Y.,
Coetzee, W. A.,
Vega-Saenz De Miera, E.,
Artman, M.,
and Rudy, B.
(1997)
Am. J. Physiol.
273,
H1775-H1786[Abstract/Free Full Text]
|
| 25.
|
Hakes, D. J.,
and Dixon, J. E.
(1992)
Anal. Biochem.
202,
293-298[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Smith, D. B.,
and Johnson, K. S.
(1988)
Gene (Amst.)
67,
31-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Frangioni, J. V.,
and Neel, B. G.
(1993)
Anal. Biochem.
210,
179-187[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Rosenfeld, J.,
Capdevielle, J.,
Guillemot, J. C.,
and Ferrara, P.
(1992)
Anal. Biochem.
203,
173-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Chen, S.-J.,
Klann, E.,
Gower, M. C.,
Powell, C. M.,
Sessoms, J. S.,
and Sweatt, J. D.
(1993)
Biochemistry
32,
1032-1039[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Cormack, B. P.,
Valdivia, R. H.,
and Falkow, S.
(1996)
Gene (Amst.)
173,
33-38[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Roberson, E. D.,
English, J. D.,
Adams, J.,
Selcher, J.,
Kondratick, C.,
and Sweatt, J. D.
(1999)
J. Neurosci.
19,
4337-4348[Abstract/Free Full Text]
|
| 32.
|
Jonas, E. A.,
and Kaczmarek, L. K.
(1996)
Curr. Opin. Neurobiol.
6,
318-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Kemp, B. E.,
Graves, D. J.,
Benjamini, E.,
and Krebs, E. G.
(1977)
J. Biol. Chem.
252,
4888-4894[Free Full Text]
|
| 34.
|
Anderson, A. E.,
Adams, J. P.,
Swann, J. W.,
Johnston, D.,
Pfaffinger, P. J.,
and Sweatt, J. D.
(1997)
Soc. Neurosci. Abstr.
23,
1394
|
| 35.
|
Anderson, A.,
Adams, J.,
Swann, J.,
Johnston, D.,
Pfaffinger, P.,
and Sweatt, J.
(1998)
Soc. Neurosci. Abstr.
24,
7
|
| 36.
|
Johns, D. C.,
Nuss, H. B.,
and Marban, E.
(1997)
J. Biol. Chem.
272,
31598-31603[Abstract/Free Full Text]
|
| 37.
|
Hoger, J. H.,
Walter, A. E.,
Vance, D., Yu, L.,
Lester, H. A.,
and Davidson, N.
(1991)
Neuron
6,
227-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Payet, M. D.,
and Dupuis, G.
(1992)
J. Biol. Chem.
267,
18270-18273[Abstract/Free Full Text]
|
| 39.
|
Perozo, E.,
and Bezanilla, F.
(1990)
Neuron
5,
685-690[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Perozo, E.,
Vandenberg, C. A.,
Jong, D. S.,
and Bezanilla, F.
(1991)
J. Gen. Physiol.
98,
1-17[Abstract/Free Full Text]
|
| 41.
|
Perozo, E.,
Jong, D. S.,
and Bezanilla, F.
(1991)
J. Gen. Physiol.
98,
19-34[Abstract/Free Full Text]
|
| 42.
|
Pak, M. D.,
Baker, K.,
Covarrubias, M.,
Butler, A.,
Ratcliffe, A.,
and Salkoff, L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4386-4390[Abstract/Free Full Text]
|
| 43.
|
Roberds, S. L.,
and Tamkun, M. M.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1798-1802[Abstract/Free Full Text]
|
| 44.
|
Baldwin, T. J.,
Tsaur, M.-L.,
Lopez, G. A.,
Jan, Y. N.,
and Jan, L. Y.
(1991)
Neuron
7,
471-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Serodio, P.,
Vega-Saenz de Miera, E.,
and Rudy, B.
(1996)
J. Neurophysiol.
75,
2174-2179[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. P. Johnson, A. F. El-Yazbi, M. F. Hughes, D. C. Schriemer, E. J. Walsh, M. P. Walsh, and W. C. Cole
Identification and Functional Characterization of Protein Kinase A-catalyzed Phosphorylation of Potassium Channel Kv1.2 at Serine 449
J. Biol. Chem.,
June 12, 2009;
284(24):
16562 - 16574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Zhang, X.-W. Fei, Y.-L. He, G. Yang, and Y.-A. Mei
Bradykinin inhibits the transient outward K+ current in mouse Schwann cells via the cAMP/PKA pathway
Am J Physiol Cell Physiol,
June 1, 2009;
296(6):
C1364 - C1372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Hammond, L. Lin, M. S. Sidorov, A. M. Wikenheiser, and D. A. Hoffman
Protein Kinase A Mediates Activity-Dependent Kv4.2 Channel Trafficking
J. Neurosci.,
July 23, 2008;
28(30):
7513 - 7519.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kim and D. A. Hoffman
Potassium Channels: Newly Found Players in Synaptic Plasticity
Neuroscientist,
June 1, 2008;
14(3):
276 - 286.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-S. Park, J.-W. Yang, E. Seikel, and J. S. Trimmer
Potassium Channel Phosphorylation in Excitable Cells: Providing Dynamic Functional Variability to a Diverse Family of Ion Channels
Physiology,
February 1, 2008;
23(1):
49 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Ke, Y.-F. Xiao, J. A. Bradbury, J. P. Graves, L. M. DeGraff, J. M. Seubert, and D. C. Zeldin
Electrophysiological Properties of Cardiomyocytes Isolated from CYP2J2 Transgenic Mice
Mol. Pharmacol.,
October 1, 2007;
72(4):
1063 - 1073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A.G. van der Heyden, T. J.M. Wijnhoven, and T. Opthof
Molecular aspects of adrenergic modulation of the transient outward current
Cardiovasc Res,
August 1, 2006;
71(3):
430 - 442.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ren, L. F. Barnwell, J. C. Alexander, F. D. Lubin, J. P. Adelman, P. J. Pfaffinger, L. A. Schrader, and A. E. Anderson
Regulation of Surface Localization of the Small Conductance Ca2+-activated Potassium Channel, Sk2, through Direct Phosphorylation by cAMP-dependent Protein Kinase
J. Biol. Chem.,
April 28, 2006;
281(17):
11769 - 11779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-L. Yuan, X. Chen, K. Kunjilwar, P. Pfaffinger, and D. Johnston
Acceleration of K+ channel inactivation by MEK inhibitor U0126
Am J Physiol Cell Physiol,
January 1, 2006;
290(1):
C165 - C171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Patel and D. L. Campbell
Transient outward potassium current, 'Ito', phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms
J. Physiol.,
November 15, 2005;
569(1):
7 - 39.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kim, D.-S. Wei, and D. A. Hoffman
Kv4 potassium channel subunits control action potential repolarization and frequency-dependent broadening in rat hippocampal CA1 pyramidal neurones
J. Physiol.,
November 15, 2005;
569(1):
41 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Kanold and P. B. Manis
Encoding the Timing of Inhibitory Inputs
J Neurophysiol,
May 1, 2005;
93(5):
2887 - 2897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gallego, R. Setien, L. Puebla, M. d. C. Boyano-Adanez, E. Arilla, and O. Casis
{alpha}1-Adrenoceptors stimulate a G{alpha}s protein and reduce the transient outward K+ current via a cAMP/PKA-mediated pathway in the rat heart
Am J Physiol Cell Physiol,
March 1, 2005;
288(3):
C577 - C585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Birnbaum, A. W. Varga, L.-L. Yuan, A. E. Anderson, J. D. Sweatt, and L. A. Schrader
Structure and Function of Kv4-Family Transient Potassium Channels
Physiol Rev,
July 1, 2004;
84(3):
803 - 833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Varga, L.-L. Yuan, A. E. Anderson, L. A. Schrader, G.-Y. Wu, J. R. Gatchel, D. Johnston, and J. D. Sweatt
Calcium-Calmodulin-Dependent Kinase II Modulates Kv4.2 Channel Expression and Upregulates Neuronal A-Type Potassium Currents
J. Neurosci.,
April 7, 2004;
24(14):
3643 - 3654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Caballero, R. Gomez, I. Moreno, L. Nunez, T. Gonzalez, C. Arias, M. Guizy, C. Valenzuela, J. Tamargo, and E. Delpon
Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current
Cardiovasc Res,
April 1, 2004;
62(1):
86 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Wong and L. C. Schlichter
Differential Recruitment of Kv1.4 and Kv4.2 to Lipid Rafts by PSD-95
J. Biol. Chem.,
January 2, 2004;
279(1):
444 - 452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Shibata, H. Misonou, C. R. Campomanes, A. E. Anderson, L. A. Schrader, L. C. Doliveira, K. I. Carroll, J. D. Sweatt, K. J. Rhodes, and J. S. Trimmer
A Fundamental Role for KChIPs in Determining the Molecular Properties and Trafficking of Kv4.2 Potassium Channels
J. Biol. Chem.,
September 19, 2003;
278(38):
36445 - 36454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Hu, K. S. Glauner, and R. W. Gereau IV
ERK Integrates PKA and PKC Signaling in Superficial Dorsal Horn Neurons. I. Modulation of A-Type K+ Currents
J Neurophysiol,
September 1, 2003;
90(3):
1671 - 1679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Schrader, A. E. Anderson, A. Mayne, P. J. Pfaffinger, and J. D. Sweatt
PKA Modulation of Kv4.2-Encoded A-Type Potassium Channels Requires Formation of a Supramolecular Complex
J. Neurosci.,
December 1, 2002;
22(23):
10123 - 10133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. C Amberg, S. D. Koh, W. J Hatton, K. J Murray, K. Monaghan, B. Horowitz, and K. M Sanders
Contribution of Kv4 channels toward the A-type potassium current in murine colonic myocytes
J. Physiol.,
October 15, 2002;
544(2):
403 - 415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. C Amberg, S. A Baker, S. D. Koh, W. J Hatton, K. J Murray, B. Horowitz, and K. M Sanders
Characterization of the A-type potassium current in murine gastric antrum
J. Physiol.,
October 15, 2002;
544(2):
417 - 428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. DeFazio and S. M. Moenter
Estradiol Feedback Alters Potassium Currents and Firing Properties of Gonadotropin-Releasing Hormone Neurons
Mol. Endocrinol.,
October 1, 2002;
16(10):
2255 - 2265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. J. Ramakers and J. F. Storm
A postsynaptic transient K+ current modulated by arachidonic acid regulates synaptic integration and threshold for LTP induction in hippocampal pyramidal cells
PNAS,
July 23, 2002;
99(15):
10144 - 10149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-L. Yuan, J. P. Adams, M. Swank, J. D. Sweatt, and D. Johnston
Protein Kinase Modulation of Dendritic K+ Channels in Hippocampus Involves a Mitogen-Activated Protein Kinase Pathway
J. Neurosci.,
June 15, 2002;
22(12):
4860 - 4868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Wong, E. W. Newell, D. G. M. Jugloff, O. T. Jones, and L. C. Schlichter
Cell Surface Targeting and Clustering Interactions between Heterologously Expressed PSD-95 and the Shal Voltage-gated Potassium Channel, Kv4.2
J. Biol. Chem.,
May 31, 2002;
277(23):
20423 - 20430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Selcher, E. J. Weeber, A. W. Varga, J. D. Sweatt, and M. Swank
Book Review: Protein Kinase Signal Transduction Cascades in Mammalian Associative Conditioning
Neuroscientist,
April 1, 2002;
8(2):
122 - 131.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Loukin, J. Lin, U. Athar, C. Palmer, and Y. Saimi
The carboxyl tail forms a discrete functional domain that blocks closure of the yeast K+ channel
PNAS,
February 19, 2002;
99(4):
1926 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Kanold and P. B. Manis
A Physiologically Based Model of Discharge Pattern Regulation by Transient K+ Currents in Cochlear Nucleus Pyramidal Cells
J Neurophysiol,
February 1, 2001;
85(2):
523 - 538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Varga, A. E. Anderson, J. P. Adams, H. Vogel, and J. D. Sweatt
Input-Specific Immunolocalization of Differentially Phosphorylated Kv4.2 in the Mouse Brain
Learn. Mem.,
September 1, 2000;
7(5):
321 - 332.
[Abstract]
[Full Text]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|